IsoRay (NYSEAMERICAN:ISR) issued its quarterly earnings data on Thursday. The healthcare company reported ($0.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01), Bloomberg Earnings reports. The company had revenue of $1.54 million during the quarter. IsoRay had a negative net margin of 127.66% and a negative return on equity of 62.92%.

Shares of IsoRay (ISR) traded down $0.01 during midday trading on Friday, reaching $0.47. 125,269 shares of the company’s stock traded hands, compared to its average volume of 158,235. IsoRay has a 1 year low of $0.38 and a 1 year high of $0.69. The firm has a market cap of $25.35, a PE ratio of -4.27 and a beta of 1.11.

Separately, Maxim Group set a $3.00 price objective on shares of IsoRay and gave the company a “buy” rating in a research note on Wednesday, November 15th.

In other IsoRay news, VP Michael Krachon purchased 55,000 shares of the firm’s stock in a transaction on Monday, November 20th. The stock was purchased at an average cost of $0.50 per share, for a total transaction of $27,500.00. Following the transaction, the vice president now owns 19,609 shares in the company, valued at approximately $9,804.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders acquired 92,440 shares of company stock valued at $44,292.

ILLEGAL ACTIVITY NOTICE: “IsoRay (ISR) Issues Quarterly Earnings Results, Misses Estimates By $0.01 EPS” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this story can be read at

About IsoRay

IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.

Earnings History for IsoRay (NYSEAMERICAN:ISR)

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.